Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML.

Leukemia research - 1 May 2024

Risueño Alberto, See Wendy L, Bluemmert Iryna, de Botton Stéphane, DiNardo Courtney D, Fathi Amir T, Schuh Andre C, Montesinos Pau, Vyas Paresh, Prebet Thomas, Gandhi Anita, Hasan Maroof

Abstract excerpt

Limited treatment options are available for patients with relapsed/refractory acute myeloid leukemia (R/R AML). We recently reported results from the phase 3 IDHENTIFY trial (NCT02577406) showing improved response rates and event-free survival with enasidenib monotherapy compared with conventional care regimens (CCR) in heavily pretreated, older patients with late-stage R/R AML bearing IDH2 mutations. Here we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Aminopyridines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Isocitrate Dehydrogenase

Share to Leukemia, Myeloid, Acute

Share to Neoplasm Recurrence, Local

Share to Prognosis

Share to Triazines

Source

Identifiers

PMID: 38564986
DOI: 10.1016/j.leukres.2024.107497

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML.PMID 38564986Read ↗

Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML.Semantic proximity Read ↗

Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study.Semantic proximity Read ↗

Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing.Semantic proximity Read ↗

Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response.Semantic proximity Read ↗

Oncogenetic landscape and clinical impact of IDH1 and IDH2 mutations in T-ALL.Semantic proximity Read ↗

The combination of NPM1, DNMT3A, and IDH1/2 mutations leads to inferior overall survival in AMLSemantic proximity Read ↗

Acquisition of IDH2 mutations in relapsed/refractory AML is associated with worse patient outcomes.Semantic proximity Read ↗

Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis.Semantic proximity Read ↗

IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.Semantic proximity Read ↗

Additional mutations in IDH1/2-mutated patients with acute myeloid leukemia.Semantic proximity Read ↗

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.Semantic proximity Read ↗

Molecular Mutations and Their Cooccurrences in Cytogenetically Normal Acute Myeloid LeukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.